Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer

被引：0
|
作者：
Thehang Luu
Kyu-pyo Kim
Suzette Blanchard
Bean Anyang
Arti Hurria
Lixin Yang
Jan H. Beumer
George Somlo
Yun Yen
机构：
[1] City of Hope Medical Center,Department of Medical Oncology
[2] OncoGambit,Cancer Therapeutics Program
[3] LLC,Department of Oncology, Asan Medical Center
[4] University of Pittsburgh Cancer Institute,Department of Biostatistics
[5] University of Ulsan College of Medicine,Department of Molecular
[6] City of Hope,Department of Pharmaceutical Sciences
[7] City of Hope,Division of Hematology/Oncology, Department of Medicine
[8] University of Pittsburgh School of Pharmacy,Pharmacology, Beckman Research Institute
[9] University of Pittsburgh School of Medicine,Cancer Research and Drug Discovery Medical Technology College
[10] City of Hope,undefined
[11] Taipei Medical University,undefined
来源：
Breast Cancer Research and Treatment | 2018年 / 167卷
关键词：
Phase IB clinical trial; Ixabepilone; Vorinostat; Metastatic breast cancer; Histone deacetylation inhibitors (HDACIs);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：469 / 478
页数：9
相关论文
共 50 条
  • [41] Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
    Neelima Denduluri
    James J. Lee
    Janice Walshe
    Arlene W. Berman
    Ujala Vatas
    Catherine K. Chow
    Seth M. Steinberg
    Michael C. Cox
    Jennifer A. Low
    Sandra M. Swain
    Investigational New Drugs, 2007, 25 : 63 - 67
  • [42] Randomized Phase III Trial of Ixabepilone Plus Capecitabine Versus Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
    Sparano, Joseph A.
    Vrdoljak, Eduard
    Rixe, Oliver
    Xu, Binghe
    Manikhas, Alexey
    Medina, Carlos
    Ventilari Da Costa, Susanne Crocamo
    Ro, Jungsil
    Rubio, Gonzalo
    Rondinon, Monica
    Perez Manga, Gumersindo
    Peck, Ronald
    Poulart, Valerie
    Conte, Pierfranco
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3256 - 3263
  • [43] Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer
    Denduluri, Neelima
    Lee, James J.
    Walshe, Janice
    Berman, Arlene W.
    Vatas, Ujala
    Chow, Catherine K.
    Steinberg, Seth M.
    Cox, Michael C.
    Low, Jennifer A.
    Swain, Sandra M.
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (01) : 63 - 67
  • [44] Preliminary Toxicity Results of a Phase II Randomized Trial of Weekly or Every 3-Week Ixabepilone in Metastatic Breast Cancer (MBC).
    Smith, I. I. J. W.
    Vukelja, S. J.
    Rabe, A. C.
    Pluenneke, R. E.
    Wentworth-Hartung, N.
    Benaderet, L. B.
    Koutrelakos, N. W.
    Robbins, G. J.
    Shao, S. H.
    Whittaker, T. L.
    Greco, A. O.
    Wang, Y.
    Boehm, K. A.
    Asmar, L.
    Opatt, D.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2009, 69 (24) : 856S - 856S
  • [45] Phase 2 clinical trial of ixabepilone in metastatic cervical carcinoma.
    Pichun, Mauricio Emmanuel Burotto
    Bala, Sanjeeve
    Edgerly, Maureen
    Wilkerson, Julia
    Velarde, Margarita
    Kotz, Herbert L.
    Bates, Susan Elaine
    Fojo, Antonio Tito
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] Phase Ib/II trial of siltuximab and spartalizumab in patients in metastatic pancreatic cancer
    Akce, Mehmet
    Shaib, Walid Labib
    Diab, Maria
    Alese, Olatunji B.
    Wu, Christina
    Thomas, Sunisha
    Greene, Emily
    Herting, Cameron
    Lesinski, Gregory B.
    El-Rayes, Bassel F.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [47] A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
    Tolaney, S. M.
    Najita, J.
    Chen, W.
    Savoie, J.
    Fornier, M.
    Krop, I. E.
    Winer, E. P.
    Bunnell, C.
    CANCER RESEARCH, 2009, 69 (02) : 243S - 243S
  • [48] Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer
    Gray, Jhanelle E.
    Saltos, Andreas
    Tanvetyanon, Tawee
    Haura, Eric B.
    Creelan, Ben
    Antonia, Scott J.
    Shafique, Michael
    Zheng, Hong
    Dai, Wenjie
    Saller, James J.
    Chen, Zhihua
    Tchekmedyian, Nishan
    Goas, Kristen
    Thapa, Ram
    Boyle, Theresa A.
    Chen, Dung-Tsa
    Beg, Amer A.
    CLINICAL CANCER RESEARCH, 2019, 25 (22) : 6623 - 6632
  • [49] Phase IB trial of ACY-1215 (ricolinostat) combined with nab-paclitaxel in metastatic breast cancer (MBC)
    Kalinsky, Kevin
    Chiuzan, Cody
    Onishi, Maika
    Trivedi, Meghna S.
    Accordino, Melissa
    Zeleke, Tizita
    Pan, Qingfei
    Kelly, Sean
    Honan, Erin
    Wu, Ruby
    Fenn, Kathleen
    Crew, Katherin D.
    Hershman, Dawn L.
    Maurer, Matthew
    Yu, Jiyang
    Silva, Jose
    CANCER RESEARCH, 2020, 80 (04)
  • [50] Phase IB trial of ACY-1215 (Ricolinostat) combined with nab-paclitaxel in metastatic breast cancer.
    Kalinsky, Kevin
    Onishi, Maika
    Yu, JiYang
    Trivedi, Meghna S.
    Accordino, Melissa Kate
    Crew, Katherine D.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345